Blood Research  2015;50(2):97-102

doi:10.5045/br.2015.50.2.97

Maximum standardized uptake value on positron emission tomography/computed tomography predicts clinical outcome in patients with relapsed or refractory diffuse large B-cell lymphoma.

Hee Ryeong JANG 1 ; Moo Kon SONG ; Joo Seop CHUNG ; Deok Hwan YANG ; Jeong Ok LEE ; Junshik HONG ; Su Hee CHO ; Seong Jang KIM ; Dong Hoon SHIN ; Young Joo PARK ; Jin Suk KANG ; Jeong Eun LEE ; Moon Won LEE ; Ho Jin SHIN

Affiliations

+expand

Keywords

Positron emission tomography; SUVmax; aa-IPI

Country

Republic of Korea

Language

English

Abstract

BACKGROUND: Few clinical studies have clarified the prognostic factors that affect clinical outcomes for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after immunochemotherapy. METHODS: A total of 158 patients with relapsed or refractory DLBCL were enrolled. All patients underwent positron emission tomography/computed tomography (PET/CT) before and after salvage therapy. All enrolled patients previously received the ifosfamide, carboplatin, and etoposide regimen. Clinical outcomes were compared according to several factors (age > or = 65 years, low age-adjusted International Prognostic Index [aa-IPI], maximum standardized uptake value [SUVmax] <6.0 on PET/CT, time to relapse > or =12 months, complete response after salvage therapy). A low aa-IPI, SUVmax <6.0, and time to relapse > or = 12 months were independent prognostic factors for survival. RESULTS: In univariate analysis and multivariate analysis, SUVmax below 6.0 (P<0.001 for progression-free survival (PFS), P<0.001 for overall survival (OS)) and low aa-IPI (P<0.001 for PFS, P<0.001 for OS) were independent prognostic factors associated with favorable outcome. CONCLUSION: The aa-IPI and initial SUVmax were powerful prognostic factors in patients with relapsed or refractory DLBCL.